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Abstract
Objectives: Obstructive sleep apnoea (OSA) might cause right ventricular dysfunction and
pulmonary hypertension. We aimed to determine the effects of nasal continuous positive airway
pressure (CPAP) therapy on right ventricular myocardial performance index (MPI) in OSA patients
without hypertension.
Methods: 49 subjects without hypertension, diabetes mellitus, any cardiac and pulmonary disease
had overnight polysomnography and echocardiography. In 18 moderate-severe OSA (apnea-
hypopnea index ≥ 15) patients, right ventricular free wall diameter (RVFWD) was measured by M-
mode, and right ventricular MPI was calculated as (isovolumic contraction time+ isovolumic
relaxation time) / pulmonary ejection time using Doppler at baseline and after 6 months CPAP
therapy.
Results: Mean age was 46.5 ± 4.9 year. Patients had high body mass index (BMI: 30.6 ± 4,0 kg/m2),
but there was no change in either BMI or blood pressures after 6 months. Right ventricular end-
diastolic and end-systolic diameters were in normal limits at baseline, and did not change after
CPAP usage. Baseline RVFWD (7.1 ± 2.1 mm) significantly decreased after CPAP therapy (6.2 ± 1.7
mm, p < 0.001). 15 of patients (83%) had right ventricular diastolic dysfunction at baseline, and it
was completely improved in 11 of them (73%) by CPAP usage. Right ventricular global dysfunction
was shown in 11 patients (61%) with a high MPI (62.2 ± 9.3%) at baseline; and MPI was significantly
decreased after CPAP therapy (47.3 ± 8.4%, p < 0.0001), and it was completely corrected in 4 of
them (36%).
Conclusion: CPAP therapy significantly decreases RVFWD and improves right ventricular
diastolic and global functions (MPI) in OSA patients without hypertension.
Introduction
The obstructive apneic event is associated with considera-
ble breathing efforts against totally or partially occluded
upper airway. Obstructive sleep apnoea (OSA) might lead
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right ventricular dysfunction, myocardial infarction,
arrhythmias, systemic and pulmonary hypertension, that
all increase morbidity and mortality [1-10]. Early recogni-
tion and appropriate therapy of ventricular dysfunction is
advisable to prevent further progression to heart failure
and death [11,12].
During an obstructive apnea, large negative intrathoracic
pressures are generated during inspiratory efforts, which
increase transmural pressures across the myocardium,
thus increasing afterload. An increase in preload and pul-
monary congestion may also occur due to increased
venous return. The presence of hypoxemia decreases oxy-
gen delivery to the myocardium, which may promote
angina and arrhythmias. Also, frequent arousals from
sleep lead to increase sympathetic activity. Other respon-
sible mechanisms include impaired vagal activity,
increased platelet aggregability, insulin resistance, and
endothelial dysfunction with reduced endogenous nitric
oxide production [13]. Continuous positive airway pres-
sure (CPAP) is known to maintain upperairway patency
during sleep by increasing transmural pressure of upper
airways, and treatment of OSA by CPAP improves cardiac
function and quality of life [14-17].
Ventricular dysfunction could not be detected clinically,
but could just be detected echocardiographically. Myocar-
dial performance index (MPI) reflects both systolic and
diastolic functions (global function) of the ventricle
[18,19]. In the presence of ventricular global dysfunction,
MPI increases in contrast to ejection fraction (EF) of the
ventricle. MPI is reproducible and a simple non-invasive
method for the estimation of ventricular global function.
In the present study, we aimed to determine the effects of
nasal CPAP after 6 months of therapy on right ventricular




49 subjects admitted to sleep clinic with symptoms of
nocturnal snoring and/or excessive day-time sleepiness
taken into the study. A detailed sleep and cardiovascular
anamnesis of the patients were recorded. Sleep cycle,
nutritional status, medications, alcohol usage and family
anamnesis were also questioned. Epworth sleepiness scale
(ESS) [20] was questioned to all patients, and patients
having high scores (ESS ≥ 10) were taken into the sleep
study.
Physical examination was performed to all subjects at
baseline and at 6 months. Systolic (SBP) and diastolic
(DBP) blood pressures were measured in the sitting posi-
tion on the right arm using a sphygmomanometer (Erka,
Germany), after at least 5 min of rest. Hypertension was
identified as blood pressure ≥ 140/90 mmHg or being
used antihypertensive drugs. Heart rate per minute (HR)
was measured in the sitting position, and body mass index
(BMI) of the patients were calculated as weight divided to
height square (kg/m2).
Pulmonary function tests (Sensor medics 2400, Nether-
lands), arterial blood gas analysis (ABL 30, Kopenhagen)
were performed to all patients at rest. A 12-leadsurface
ECG was taken from every subject, and all of them were in
sinus rhythm. Also, all of subjects underwent treadmill
exercise test and, the test was normal for each subject.
Symptoms of nocturnal snoring and/or excessive day-time
sleepiness were accepted as inclusion criteria. Exclusion
criteria of the study were the presence of 1- any known car-
diac and lung disease, 2- hypertension, 3- diabetes melli-
tus, 4- angina pectoris, 5- atrial fibrillation or any
arrhythmias, 6- chronic renal and hepatic diseases, 7-
serum electrolytes imbalances.
b) Polysomnography (PSG)
All patients underwent an entire night of diagnostic PSG
while breathing room air, followed a second night of PSG
with nasal CPAP titration [21]. The portable, limited sleep
study performed with the Emblettadevice [22], consisted
of the following: 1) nasal pressure detectorusing nasal
cannulae/pressure transducer system, recording thesquare
root of pressure as an index of flow; 2) thoraco-abdomi-
Table 1: Baseline characteristics of obstructive sleep apnea 
patients without hypertension at pre-treatment of continuous 
positive airway pressure (CPAP).
Variables Data
Subjects n 18
Mean age yrs 46.5 ± 4.9
Male n, (%) 14 (78)
Female n, (%) 4 (22)
BMI kg/m2 30.6 ± 4,0
SBP mmHg 120.3 ± 10.1
DBP mmHg 82.0 ± 4.1
HR pulse*min-1 82.4 ± 13.4
AHI per h 50.1 ± 11.6
DI per h 37.8 ± 18.0
MinSatO2 (%) 73.8 ± 18.9
AverageSatO2 % 80.1 ± 2.6
*Sleep duration % 66.4
CPAP usage h/night 5.6 ± 1.7
CPAP pressure cmH2O 11.3 ± 2.5
Data are presented as n, n(%) or mean ± SD. BMI: body mass index, 
SBP: systolic blood pressure, DBP: diastolic blood pressure, HR: heart 
rate, AHI: apnea hypopnea index, DI: desaturation index, SatO2: 
saturation of nocturnal arterial oxygen, NS: nonsignificant. *SatO2 < 
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3) fingerpulse oximeter; and 4) body position detection.
Apnea was defined as total obstruction of oronasal airflow
≥ 10 seconds, an hypopnea was defined as decrease of air-
flow at least 50%, and desaturation was accepted as a
decrease of ≥ 4% in oxygen saturation [23]. Desaturation
index (DI) was identified as number of oxygen desatura-
tion events per hour of sleep. In this study, 21 non-hyper-
tensive subjects with AHI ≥ 15 were diagnosed as
moderate-severe OSA [24].
c) Nasal continuous positive airway pressure (CPAP)
Patients with severe OSA were prescribed nasal CPAP
(Remstarplus, Respironics Corporation; Murrysville,
Pennsylvania, USA), including use of a heated humidifier.
The CPAP machines were equipped with compliance
monitors that measured CPAP use, in order to observe
CPAP usage/compliance at home. Routine troubleshoot-
ing took place in an effort to maximize compliance with
nasal CPAP. Patients were considered to be CPAP compli-
ant if they used CPAP an average ≥ 3.5 h per night at the
6-month follow-up.
d) Echocardiographic measurements
Echocardiograms were obtained following the diagnosis
of OSA and prior to initiation of CPAP, and at 6 months.
All measurements were performed with the subjects in the
left lateral decubitus position by M mode, two dimen-
sional (2D), and Doppler ultrasound echocardiography
in the morning. The ultrasound equipment used was Con-
tron Sigma Iris with a 2.5-MHz probe. The duration of the
examination was at least 20 minutes. The ventricular
diameters, volumes and functions were measured accord-
ing to the recommendations of the American Society of
Echocardiography [25]. Basic measurements of left/right
ventricular dimensions in diastole and systole, thickness
of interventricular septum (IVS), left ventricular posterior
wall (LVPW) and right ventricular free wall diameter
(RVFWD) were measured by M-mode technique.
Early (E) and atrial (A) trans-mitral/tricuspid maximal
flow velocities, the ratio (E/A) and deceleration time (DT)
of E was registered. Isovolumetric relaxation time (IVRT)
was measured by the continuous wave Doppler tech-
nique. The velocity of mitral/tricuspid flow propagation
(VPR) was estimated using color Doppler M-mode. The
left/right ventricular MPI was calculated as (isovolumic
contraction time of left/right ventricle + IVRT of left/right
ventricle) / (aortic/pulmonary ejection time) by Doppler.
e) Statistical analysis
Measurements are expressed as mean ± SD. A Wilcoxon
test for related measurements was used to compare pri-
mary outcome variables of both IVS, LVPW, RVFWD and
ventricular functions (LVEF, MPI) at baseline and 6
Table 2: Basic characteristics and left ventricular structure and function indices in overall obstructive sleep apnoea patients before and 
after 6 months of continuous positive airway pressure (CPAP) treatment.
CPAP treatment p-value
Overall (n = 18) Before After
Basic characteristics
BMI kg*m-2 (<30)* 30.6 ± 4,0 31,0 ± 3,5 NS
SBP mmHg (<140)* 120.3 ± 10.1 119,1 ± 10,2 NS
DBP mmHg (<90)* 82.0 ± 4.1 81.2 ± 3,8 NS
Left ventricular structure
Left atrium mm (19–40)* 35.1 ± 3.2 36.0 ± 3.0 NS
IVS thickness mm (6–11)* 10.3 ± 1.1 10,4 ± 1,0 NS
LVPW thickness mm (6–11)* 10.1 ± 0.8 10,0 ± 0,9 NS
LVEDD mm (37–56)* 47.1 ± 4.1 46.1 ± 4.3 NS
LVESD mm (19–40)* 32.2 ± 4.8 31.8 ± 4.7 NS
Diastolic functions
E/A ratio (>1)* 1.6 ± 0.1 1.6 ± 0.2 NS
IVRT ms (<100)* 80.0 ± 12.0 81.1 ± 12.6 NS
DT ms (<220)* 180.2 ± 16.5 179.5 ± 16.8 NS
VPR cm*s-1 (>55)* 89.2 ± 10.6 88.6 ± 10.3 NS
Systolic function
LVEF % (55–75)* 64.0 ± 4.9 64,1 ± 4,7 NS
Global function
MPI % (39 ± 5)* 37.2 ± 6.0 36.8 ± 5.8 NS
Data are presented as mean ± SD. *Normal values, BMI: Body mass index, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, IVS: 
Ýnterventricular septum, LVPW: Left ventricular posterior wall, LVEDD: Left ventricular end diastolic diameter, LVESD: Left ventricular end 
systolic diameter, E/A: Ratio of early and lately mitral flow velocity, IVRT: Ýsovolumic relaxation time, DT: Mitral deceleration time, VPR: Velocity 
of mitral flow propagation, LVEF: Left ventricular ejection fraction, MPI: Myocardial performance index of left ventricle, NS: nonsignificant.Page 3 of 8
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comparison of number of obstructive sleep apnea patients
without hypertension according to right ventricular
hypertrophy and diastolic or global dysfunctions at base-
line (before treatment) and after 6 months of CPAP usage.
A p value of < 0.05 was regarded as significant.
Results
18 of 21 patients were compliant with CPAP therapy,
which we defined as ≥ 3.5 h of nightly use. At the end of
the study the mean daily CPAP usage of 18 patients, was
5.6 ± 1.7 h per night. The 3 patients who were non-com-
pliant with nasal CPAP were excluded. So, 14 males
(78%) and 4 females (22%) with moderate-severe OSA
without hypertension were included in the study. Mean
age of patients was 46.5 ± 4.9 year. None of them were
using alcohol, and 55% of them were smoking cigarettes.
Baseline characteristics of OSA patients were shown in
table 1. Study patients had high BMI (mean 30.6 ± 4,0 kg/
m2), however there were no change in either BMI or blood
pressures (BP) after 6 months (see table 2). Mean AHI was
50.1 ± 11.6 per h, average O2 saturation was 80.1 ± 2.6%
and sleep duration with oxygen saturation <90% was
66.4% in the patients (table 1).
Compliance of CPAP
The major reasons for noncompliance were mask discom-
fort or pressure intolerance. All subjects were offered
heated humidity, and efforts were made in all subjects to
improve comfort and compliance with therapy. Average
CPAP pressure after 6 months of therapy did not change
from the initial CPAP pressure that was prescribed (11.3 ±
2.5 cmH2O and 11.0 ± 2,3 cmH2O).
Echocardiographic findings before and after CPAP therapy
Baseline characteristics and left ventricular structure and
function indices in OSA patients before and after 6
months of CPAP treatment were shown in table 2. All
echocardiographic left ventricular structural (e.g. IVS,
LVPW diameters) and functional (e.g. E/A ratio, LVEF and
MPI) parameters were in normal limits, and all of them
did not significantly change after 6 months of CPAP ther-
apy in OSA patients without hypertension.
Right ventricular structure and function indices in the
patients before and after 6 months of CPAP treatment
were shown in table 3. Although right atrial and right ven-
tricular end-diastolic diameters were in normal limits, and
both of them did not significantly change; right ventricu-
lar free wall diameter at baseline (7.1 ± 2.1 mm) signifi-
cantly decreased (6.2 ± 1.7 mm, p < 0.001) after CPAP
usage.
Although patients had right ventricular diastolic dysfunc-
tion with an increased mean value of diastolic function
parameters such as E/A ratio, IVRT, DT and VPR at base-
line; average value of all those parameters significantly
decreased by CPAP therapy. Also, right ventricular MPI
(62.2 ± 9.3%) was significantly decreased after 6 months
of CPAP usage (47.3 ± 8.4%, p < 0.0001), but it did not
come to the normal limits, and it still reflected right ven-
tricular global dysfunction (see table 3).
Comparison of number of OSA patients without hyper-
tension according to right ventricular hypertrophy (RVH)
and diastolic or global dysfunctions at baseline (before
treatment) and after 6 months of CPAP usage was shown
Table 3: Right ventricular structure and function indices in overall obstructive sleep apnoea patients before and after 6 months of 
continuous positive airway pressure (CPAP) treatment.
CPAP treatment p-value
Overall (n = 18) Before After
Right atrium mm 23.9 ± 3.0 23.7 ± 3.2 NS
RVFWD mm (5–8) 7.1 ± 2.1 6.2 ± 1.7 0.001
RVEDD mm (9–26) 25.4 ± 3.6 25.0 ± 3.3 NS
E-velocity (m/s) 0.4 ± 0.1 0.6 ± 0.1 0.0001
A-velocity (m/s) 0.6 ± 0.13 0.5 ± 0.9 0.001
E/A ratio (>1)* 0,7 ± 0.1 1.2 ± 0.2 0.0001
IVRT ms (<100)* 106.9 ± 24.0 91.1 ± 18.6 0.001
DT ms (<220)* 245.5 ± 61.0 210.2 ± 46.8 0.001
VPR cm*s-1 (>55)* 41.1 ± 9.9 60.9 ± 10.2 0.0001
MPI % (39 ± 5)* 62.2 ± 9.3 47.3 ± 8.4 0,0001
Data are presented as mean ± SD. *Normal values, RVFWD: Right ventricular free wall diameter, RVEDD: Right ventricle end-diastolic diameter, E- 
velocity: Early tricuspid flow velocity, A- velocity: Lately tricuspid flow velocity, E/A: Ratio of early and lately tricuspid flow velocity, IVRT: 
Ýsovolumic relaxation time, DT: tricuspid deceleration time, VPR: Velocity of tricuspid flow propagation, MPI: Myocardial performance index of 
right ventricle, NS: nonsignificant.Page 4 of 8
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although RVH had improved by CPAP usage, there was
still 3 patients having RVH at the end of 6 months. Fifteen
of 18 patients (83%) had right ventricular diastolic dys-
function, and 11 of them (73%) completely improved by
CPAP usage. Right ventricular global function (MPI) was
shown in 11 patients (61%), and also 4 of them (36%)
completely improved by CPAP therapy.
Discussion
In our previous studies, we showed right and left ventricu-
lar global dysfunctions in OSA patients with an increased
MPI [3,4]. Arterial hypertension, obesity, diabetes melli-
tus and coronary artery disease which often have coex-
istince with OSA are independent predictors of ventricular
dysfunction. On the other hand, it's well known that OSA
might cause cardiovascular complications such as heart
failure, myocardial infarction, arryhthmias, systemic and
pulmonary hypertension which all increase mortality and
morbidity [1-10]. Continuous positive airway pressure is
known to maintain upperairway patency during sleep by
increasing transmural pressure of upper airways, and
treatment of OSA by CPAP improves cardiac function and
quality of life [14-17]. In the present study, we aimed to
determine the effects of nasal CPAP after 6 months of
therapy on right ventricular structure and global function
(MPI) in moderate-severe OSA patients without hyperten-
sion.
In our study, we excluded systemic hypertension, diabetes
mellitus, coronary artery disease and any pulmonary dis-
eases including chronic obstructive pulmonary disease,
and there were no significant differences in BMI or BPs
after 6 months of therapy. Thus, we assessed the ventricu-
lar structure and functions (MPI) in uncomplicated (iso-
lated) OSA patients.
Left ventricular systolic and/or diastolic functions provide
prognostic information in the patients. In our study, left
ventricular diameters and both systolic and diastolic func-
tions of all subjects were in normal limits and did not sig-
nificantly change after CPAP therapy. However, right
ventricular free wall diameter significantly decreased after
CPAP usage. Eleven of 15 patients having diastolic dys-
function (73%) and 4 of 11 patients having right ventricu-
lar global dysfunction (36%) completely improved by
CPAP therapy.
The relation of OSA to right heart structure and function
is controversial. The prevalence of RVH by echocardiogra-
phy in sleep apnea was ranged from 0 to 71% [26]. In the
present study, 3 of 18 patients (17%) had RVH, and it was
significantly improved by CPAP usage inspite of any
change in the number of patients having RVH. It has been
argued that concomitantchronic pulmonary disorders are
required for sleep apnea to causeright heart failure [27-
31]. However, Sannerand colleagues demonstrated that
sleep apnea was independentlyassociated with depressed
right ventricular ejection fraction by radionuclideven-
triculography after adjusting for lung function, age, body-
mass index, sex, blood gas analysis, pulmonary artery
pressure, and left ventricular ejection fraction [32]. Hanly
and colleagues found no difference in right or left ven-
tricular dimensions betweennonapneic snorers and sub-
jects with OSA [33].
The reasons for the disparate conclusions of the prior
studies examining RVH, systolic function, and right ven-
tricular enlargementare not certain. In a study, right atrial
and ventricular dimensions, and right ventricular systolic-
function were not found to be significantly different
betweensubjects with sleep-disordered breathing and the
low respiratory disturbance index subjects, but this study
indicated that sleep-disordered breathing was associated
with increased right ventricular wall thickness in a general
population [34]. Right atrial and ventricular diameters of
our patients without hypertension were in normal limits
at baseline, and none of them significantly have changed
by CPAP usage.
In many studies beneficial effect of CPAP on cardiac func-
tions have been shown [35-37]. These may include several
factors, such as improved myocardialoxygen delivery,
decreased sympathetic activity, left ventriculartransmural
pressure, and afterload. In a study, Arabi et al. had proved
that systemic hypertension developed in hypoxic situa-
tion in normotensive cases, and furthermore they showed
a decrease in the adrenergic mediators in patients having
Table 4: Comparison of number of obstructive sleep apnea patients without hypertension according to right ventricular hypertrophy 
(RVH) and diastolic or global dysfunctions at baseline (before treatment) and after 6 months of continuous positive airway pressure 
(CPAP) usage.
CPAP treatment p- value
Overall (n = 18) Before After
Patients with RVH n (%) 3 (17) 3 (17) NS
Diastolic dysfunction n (%) 15 (83) 4 (22) 0,0001
Global dysfuntion n (%) 11 (61) 7 (39) 0,001
Data are presented as n or n (%), NS: nonsignificant.Page 5 of 8
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showed a regression of left ventricular hypertrophy by 6
months of CPAP therapy, but not in the left and right
atrial enlargement [39]. Recent placebo-controlled trials
have revealed reductions of up to 10 mmHg in systolic
and diastolic pressures with CPAP therapy [40-42]. How-
ever, we did not show any decrease in BPs with CPAP ther-
apy in our non-hypertensive OSA patients. The reason of
no change in BP might be due to the small sample size of
our study population, and it might depend on totally nor-
motensive patients. In our another study, we showed that
CPAP therapy in OSA patients with hypertension did not
decrease BPs and heart rates acutely, but reduced the vari-
ability of these parameters during sleep [17].
Doherty LS, et all. performed a long-term follow-up study
of 168 patients with OSA who had begun receiving CPAP
therapy at least 5 years previously, most of whom had
been prospectively followed up, having been the subject
of an earlier report on cardiovascular risk factors in OSA
patients with the average follow-up period 7.5 years [43].
They compared the cardiovascular outcomes of those
patients who were intolerant of CPAP (untreated group,
61 patients) with those continuing CPAP therapy (107
patients). Deaths from cardiovascular disease were more
common in the untreated group than in the CPAP-treated
group during follow-up (14.8% vs 1.9%, respectively; p <
0.009), but no significant differences were found in the
development of new cases of hypertension, cardiac disor-
der, or stroke. Total cardiovascular events (ie, death and
new cardiovascular disease combined) were more com-
mon in the untreated group than in the CPAP-treated
group (31% vs 18%, respectively; p < 0.05). They con-
cluded that their results support a protective effect of
CPAP therapy against death from cardiovascular disease
in patients with OSA.
Our study does not clarify the reasons of right ventricular
diastolic and global dysfunctions in OSA patients without
hypertension. Right ventricular diastolic filling is a com-
plex event that is influenced by several factors, such as
right ventricular relaxation, right ventricular compliance,
right atrium contraction force and pulmonary artery
resistance. Thus, right ventricular dysfunction might be
the result of a variety of these impairments. In our study
patients, intermittent nocturnal hypoxemia might have
caused RVH and/or right ventricular dysfunction, since
they had more hypoxic duration in their sleep with the
highest percent of sleep duration below 90% of oxygen
saturation.
Comparison of right ventricular myocardial performance index (MPI) before and after 6 months CPAP therapy in obstructive sleep apnea patients without hypertensionFigure 1
Comparison of right ventricular myocardial performance index (MPI) before and after 6 months CPAP therapy in obstructive 
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coexist, it was shown that a combined measure of ven-
tricular performance with calculation of MPI might be
more reflective of overall cardiac dysfunction than systolic
or diastolic measures alone. MPI is a simple and reproduc-
ible non-invasive method for diagnosis of ventricular glo-
bal dysfunction in patients with OSA.
In the present study, a very noticeable finding is the
improvement of right ventricular free wall dimension and
global dysfunction with a significantly decreased MPI by
CPAP therapy, even if 6 months usage.
Conclusion
OSA patients, especially having diastolic dysfunction, is in
an increased risk of heart failure, since the systolic and
diastolic dysfunction frequently coexist. A combined
measure of ventricular performance with the calculation
of MPI might be more reflective of overall cardiac dysfunc-
tion than systolic or diastolic measures alone. CPAP ther-
apy significantly decreases right ventricular free wall
thickness and improves global dysfunction with a signifi-
cantly decreased MPI even if 6 months of CPAP usage. We
consider that much longer-term usage of CPAP therapy
may achieve complete improvement of right ventricular
global dysfunction in patients with OSA.
Study limitations
Small number of patients in our study population is an
important study limitation to determine the effects of
CPAP on RVH and right ventricular dysfunction. Also, our
sleep clinic population may not reflect the findings in the
general community. A larger population of study subjects
would be helpful to determine the effects of CPAP on
right ventricular structure and function.
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